Funding Resources
Funding Overview
Funding Strategy
Funding Opportunities
Grant Mechanisms
Training & Career
Development
Contracts Management
Review Committees
Funding News
Program Areas
Research
Anticonvulsant Screening
Program
Clinical Research
Counterterrorism
Epilepsy Research Web |
NINDS is part of the
National Institutes of
Health
Feature |
---|
Videos, Slides and Photos from the Conference Now Available!
|
Epilepsy is a disorder characterized by recurring seizures, which are disturbances in the electrical activity in the brain. Seizure types range from a momentary disruption of senses to a loss of consciousness and violent movements that can last for minutes. Epilepsy affects people of all ages, from infants to the aged. There is no single cause for epilepsy; however epilepsy can sometimes be associated with a positive family history, illness, head injury, or abnormal brain development. It is estimated that 1-2% of the population has epilepsy, and of those individuals, approximately two-thirds respond well to medical treatment. NIH/NINDS and its community-based research partners are dedicated to finding a cure and/or preventing epilepsy in individuals who have or are at risk for seizures. This web page is designed to provide some information about ongoing epilepsy research efforts.
Select this link for more information about epilepsy: NINDS Epilepsy Information Page
New! NINDS publication: Curing Epilepsy: The Promise of Research
Table of Contents (click to jump to sections)
"Benchmarks" for Epilepsy Research
NINDS Anticonvulsant Screening Program
The Judith Hoyer Lecture on Epilepsy
Workshop Summaries
Workshop Publications
Recent Initiatives
Congressional Appropriations Committee Reports
Additional Links
Anticonvulsant Screening Program (ASP) is a long-standing government sponsored effort established to encourage and facilitate the discovery, optimization and development of new therapeutic agents for the treatment of seizure related disorders. One of the ASP's major goals is to establish international collaborative partnerships among governments, academia, and industry that act to stimulate the search and development of better treatments and an eventual cure for the epilepsies. Recently, through a broader HHS funded effort, the ASP has expanded its screening capabilities. We are now accepting compounds intended to act as counter-measures against potential chemical threats stemming from either intentional or accidental exposure to various nerve agents. For this purpose, the ASP now employs a series of models that mimic the effects of CNS exposure to nerve agents (actual nerve agents are not used in evaluations). To participate or for more information please contact a member of our program staff listed in our website (http://www.ninds.nih.gov/asp)..
Select this link to view additional information about the NINDS ASP program
Select this link to view additional NINDS funding information by program area
Last updated September 10, 2008